GPT and anemia: The most common treatment-related AEs reported in ≥15% of the patients across both dose levels included stomatitis (75.0%), nausea (66.7%), decreased appetite (58.3%), diarrhea, decreased platelet count, anemia (41.7%, each), increased blood creatinine, fatigue, hyperglycemia, hypophosphatemia, proteinuria, vomiting (33.3%, each), increased alanine aminotransferase, increased aspartate aminotransferase, rash, pruritus (25.0%, each), hypokalemia, hypotension, pyrexia, decreased weight, and decreased white blood cell count (16.7%, each).